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Background: Genetic counseling for hereditary breast or colon cancer has implications for both counselees
and their relatives. Although counselees are encouraged by genetic counselors to disclose genetic cancer risk
information, they do not always share this information with their at-risk relatives. Reasons for not informing
relatives may be generally categorized as a lack of knowledge, motivation and/or self-efficacy. Presented here
is the protocol of a randomized controlled trial that aims to establish the effectiveness of an intervention
focused on supporting counselees in their disclosure of genetic cancer information to their relatives.
Methods/Design: A multicenter randomized controlled trial with parallel group design will be used to compare
the effects of an additional telephone counseling session performed by psychosocial workers to enhance the
disclosure of genetic cancer information to at-risk relatives (intervention group) with a control group of standard
care. Consecutive index patients with relatives at risk for hereditary or familial breast and/or ovarian cancer or
colon cancer, are randomly assigned (block size: 8; 1:1 allocation ratio) to the intervention (n = 132) or control
group (n = 132, standard care). Primary outcomes are counselees’ knowledge, motivation and self-efficacy
regarding informing their relatives.
Discussion: This intervention may prove important in supporting counselees to disclose hereditary and/or familial
cancer risk information to at-risk relatives and may enable more at-risk relatives to make a well-informed decision
regarding genetic services and/or screening.
Trial registration: This trial is registered in the Netherlands National Trial Register (NTR) with trial ID number
NTR3745.
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Identification of hereditary or familial breast or colorectal
cancer risks has implications not only for counselees but
also for their relatives. Knowledge of genetic test results in
families is important to individualize recommendations
for risk reduction for at-risk relatives (that is, DNA testing,
regular breast or colon screening and/or (prophylactic)
surgery) [1-3].
According to international [4] and Dutch [5] guide-
lines, genetic counselors encourage counselees to inform* Correspondence: e.degeus@amc.uva.nl
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unless otherwise stated.at-risk relatives about their genetic test result and the
availability of surveillance options. Thereby, genetic coun-
selors face the challenge of encouraging counselees to
inform their relatives to enable them to make an informed
decision about their own health, while also supporting
counselees’ autonomy [6]. The counselees’ wish not to
inform relatives has to be respected, and relatives’
wish not to know has to be taken into account since
they may consider the information to be an invasion of
their own privacy [7].
Although counselees report that they generally feel
responsible to disclose genetic risk information to relatives
[8-10], they do not always succeed in correctly informing
all relevant relatives [11-15]. As a result, relatives may lackl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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whether or not to pursue genetic counseling, DNA testing
and/or surveillance activities [4,16].
To date, several (mostly qualitative studies) have ad-
dressed counselees’ barriers to informing their relatives
[14,15,17,18]. Barriers may be categorized as lack of know-
ledge, lack of motivation, and lack of self-efficacy. When
counselees have a lack of knowledge, their understanding
of family members that ought to be informed may not be
sufficient [18,19]; moreover, insufficient knowledge may
lead to incorrect disclosure [20]. A lack of motivation,
may be due to the desire to protect the relative or oneself,
for example, from negative reactions by the relative [10].
Moreover, counselees may consider a relative to be too
emotionally fragile to burden them with genetic cancer
information [19], or relatives may be perceived as not
mature enough to understand the information [21] or as
too old and, therefore, no longer in a high-risk life stage
[14]. A lack of self-efficacy may lead to counselees feeling
unable to inform their relatives. The counselee does not
deliberately withhold information but may feel insecure
about correctly disclosing the complex or burdensome
information [22].
As a result of feeling responsible about the need to
inform relatives, but at the same time facing several
barriers, counselees may experience their messenger role
as a burden [23]. Indeed, cancer genetic counselees report
a need in genetic counseling for information and support
in communicating the genetic information to others
[24,25]. Counselees also express that their lack of con-
fidence in disseminating information may be improved by
more professional backup [7].
To address the need to support counselees and the call
for an intervention by others [26,27], various interventions
have been developed to improve family communication
about genetic testing and screening options [28-31]. These
interventions mainly comprise enhanced information
[29,31] or communication skills training [28,31] for
counselees. However, no effects on facilitating the family
communication process were found, except for improving
counselees’ satisfaction [31]. One study developed a coun-
seling intervention to support counselees in communicat-
ing genetic information to at-risk relatives; this intervention
comprised the use of a pedigree chart (for example, a docu-
ment to record medical family history) to explicitly identify
at-risk relatives, a follow-up letter stressing the importance
of family disclosure, and two follow-up telephone calls
during which it was documented which relatives had been
informed and offering guidance about how to approach
relatives [32]. Investigation of the effectiveness of this
intervention indicated that the proportion of at-risk
relatives using genetic services was larger in the inter-
vention group (61%) compared with the control group
(36%); however, this latter study had a cohort design(instead of a randomized design) thereby limiting the
possibility to draw firm conclusions [32].
This paper describes the design of a randomized con-
trolled trial (RCT) for investigating the effectiveness of an
intervention based on the principles of Motivational
Interviewing (MI) [31]. MI is a client-centered counseling
style that helps individuals change health-related behavior,
such as sharing hereditary cancer risk information with
relatives. We consider that this client-centered but direct-
ive counseling style of MI is well suited for counselors,
since they have to discuss family communication with
counselees while at the same time respecting counselees’
autonomy.
The intervention, consisting of an additional telephone
counseling session conducted by psychosocial workers,
aims to support counselees in disclosing hereditary or
familial cancer risk information to at-risk relatives. This
paper presents details of the design of this RCT, guided
by the CONSORT checklist [33].
This RCT (registered in the Dutch National Trial Regis-
ter: NTR3745) aims to test the following hypotheses:
Hypothesis 1 - The intervention will increase coun-
selees’ knowledge, motivation and self-efficacy with regard
to informing relatives about their hereditary or familial
cancer risk, as compared with counselees who receive
standard care.
Hypothesis 2 - The intervention will lead to more at-
risk relatives being informed by counselees; increased
knowledge among relatives about hereditary/familial can-
cer and preventive measures; and increased intention of
informed relatives to engage in genetic counseling, testing
and/or preventive measures, compared with the standard
care condition.
Hypothesis 3 - The intervention will be positively
evaluated by counselees and psychosocial workers.
Methods/Design
Trial design
The study comprises a multicenter RCT with a parallel
group design, comparing the effects of an additional tele-
phonic counseling session aimed at supporting counselees
in informing their at-risk relatives (intervention group),
with a control condition of standard care only. Participating
counselees will complete a questionnaire at three moments:
1. Pre-intervention (T1), after receiving a
summary letter from the genetic counselor,
2. Post-intervention (T2), immediately
following the intervention, or -in standard
care - at the same time (about 4 weeks after T1),
3. Follow-up (T3) at 4 months after T1.
At T2 counselees are telephoned to complete items
regarding their insight as to who to inform and their
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hind the telephone intervention is that these items are
too complex to complete alone. At T3, participants will
invite at-risk relatives to also complete a questionnaire
(Figure 1).
Participants
Consecutive counselees visiting the department of Clinical
Genetics of three university hospitals in the Netherlands
will be recruited. The sample comprises the following
groups of counselees: those with conclusive test resultsFigure 1 Flowchart of the randomization procedure, intervention and(a pathogenic mutation has been found), those with an in-
conclusive test result, and those in whom DNA testing is
not possible. For the latter two groups there is an in-
creased cancer risk based on family history.
Inclusion criteria
Participants will be counselees who: 1) are the first in
their family to visit the Clinical Genetics department for
hereditary or familial colon or breast and/or ovarian
cancer (referred to as: index patients); 2) have at least
one relative at increased risk, that is, eligible for geneticdata collection.
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are able to read/write Dutch.
Relatives
At T3, the first, second and third-degree relatives are in-
vited by the counselee to complete a single questionnaire.
Eligible relatives are at increased risk (that is, eligible for
genetic testing and/or regular surveillance), are aged
≥18 years, and able to read and write Dutch.
Recruitment and informed consent
Counselees
In the Netherlands, it is considered standard care for the
Clinical Genetics department to send counselees a sum-
mary letter after the last counseling session; this letter
reaffirms the information provided and aims to facilitate
the communication process in the family. When this let-
ter has been received, clinical geneticists and counselors
will invite eligible counselees to participate using an in-
formation letter, an informed consent form, a return slip
to decline participation, and an invitation to complete a
(web-based) questionnaire (T1).
We will use a two-stage randomization and a consent
procedure with consent to postponed information [34-36].
In this procedure, counselees are masked for the exact
study objective. However, they are informed that: 1) the
study aims to assess issues pertaining to family disclosure,
2) the study has an additional purpose, and 3) a letter with
the postponed information about the additional research
question and reasons for not informing them during
recruitment will be sent after the study. Postponed infor-
mation enables a blind design and avoids a less favorable
outcome in the control group resulting from their know-
ledge that the other counselees receive extra care. This
procedure has been used previously and resulted in no
major objections [35-38].
In case of consent, counselees will be asked to complete
a web-based baseline questionnaire (if preferred, a paper
version of the questionnaire is available). Counselees will
then be randomized (Figure 1). Counselees in the inter-
vention group will receive an information letter about the
additional counseling, an informed consent form for the
intervention, and a return slip to decline participation.
Within one week they will be contacted by telephone to
provide them with additional information about the inter-
vention and are asked for their consent. Counselees in the
control group will receive no additional information.
Information about the randomization procedure will be
included in the debriefing letter for counselees, which is
sent after the study.
Relatives
In the Netherlands, medical-ethical regulations preclude
counselors/researchers from directly approaching acounselee’s relatives. Therefore, at T3 all counselees will
be asked to inform their relatives about the study. In case
of consent, counselees will receive more detailed informa-
tion and the family pedigree will be used to decide which
individuals are eligible for study inclusion. Then, coun-
selees will be asked to invite (by mail) their eligible first,
second and third-degree relatives to participate in the
study. For this, they can use an introductory letter, a ques-
tionnaire and a return envelope, which are made available
by the researchers. Relatives willing to participate
complete the questionnaire, thereby giving their consent,
and return the questionnaire to the researchers. Re-
searchers do not collect the full names/addresses of the
relatives but assign a study ID number to each relative. In
case of nonresponse, counselees will be asked to send
their relatives a reminder after three weeks.
Control group
Counselees in the control group will receive standard care
only. It is recommended by the Dutch Society for Clinical
Genetics that, during the first consultation, counselees are
informed about the possible consequences of genetic test-
ing for their relatives [5]. If the genetic counseling result is
relevant for relatives, counselees are asked to inform their
at-risk relatives. After the last counseling session, coun-
selees receive a summary letter which reaffirms the
information provided during the counseling. In case
of hereditary cancer, a separate family letter is provided
about the test results and recommendations for surveil-
lance measures for the counselees and their relatives. In
the Netherlands, although all departments of Genetics
consider providing these letters as part of standard care,
no specific guidelines are available; this implies that some
differences may exist between these letters.
Intervention group
Counselees in the intervention group will receive an
additional counseling session provided by psychosocial
workers specialized in genetics, aimed at supporting
them to inform their at-risk relatives. The intervention
will be delivered by telephone. The rationale for this
method is that: 1) this allows for contact with counselees
with limited knowledge/motivation to inform relatives
and who are therefore unlikely to visit the department
for additional counseling, 2) a telephone intervention is
more likely to be implemented in daily care, and 3) a
telephone-based intervention was earlier found to be
effective in increasing the number of relatives that
attended genetic services [32].
We developed a five-step model for the additional
counseling session [39] (Table 1) based, in part, on the
work of Rollnick et al. [40]. Their directive client-centered
counseling style, known as Motivational Interviewing
(MI), elicits behavior change by helping clients to explore
Table 1 Intervention elements
Phase 1: exploring
Step 1 Agenda setting Introducing the subject of family communication about hereditary or familial cancer risks and preventive
measures. Explicitly ask the counselee if he/she is willing to discuss this issue.
Step 2 Exploring Systematically exploring counselees’ current and planned pattern of informing relatives. Psychosocial workers
investigate whether the counselee correctly knows which family members are at risk and which information
should be provided to them.
Evaluation After the first phase the psychosocial worker verifies whether or not all at-risk relatives are informed thoroughly
(thoroughly = at least the written advice in the summary letter). If the counselee has informed all at-risk relatives
properly the psychosocial worker will end the counseling session. If not, the psychosocial worker will start phase 2.
Phase 2: additional information and brainstorming
Step 3 Additional information Additional or corrective information is provided, if needed. For example, in case of BRCA 1/2 it is important to
stress that male relatives can also transmit the risk and thus need to be informed.
Step 4 Building motivation The purpose of the fourth phase is to build motivation and strengthen self-efficacy. Psychosocial workers invite
counselees to verbalize arguments in favor of informing relatives, to reinforce these arguments and thus
strengthen the counselees’ motivation. Any barriers are also assessed and discussed. These barriers can be
practical, for example, not having personal contact, and/or emotional, for example, causing too much distress.
Also, reasons for (non)disclosure are explored, so as to understand the counselee’s perspective and motives,
to build rapport and reduce resistance. Likewise, the counselees’ confidence in their ability to correctly and
sufficiently inform relatives is assessed and strengthened.
Step 5 Brainstorming During the final phase, the psychosocial worker invites the counselee to engage in active brainstorming on
possible solutions for informing more difficult to approach relatives. The goal is to develop a plan for
informing these relatives.
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ing principles: expressing empathy by use of reflective lis-
tening, developing discrepancy between goals and current
behavior, assuming that clients are responsible for the
decision to act or not, rolling with resistance rather than
confronting, and supporting self-efficacy.
The intervention is delivered by one of five psychosocial
workers. All will have attended two days of training days
provided by two trainers from the department of Medical
Psychology (AMC) who have extensive experience with
MI. These sessions provide more information about MI
and the intervention. Moreover, interviewing techniques
are practiced with a trained actor and individual feedback
is provided by the trainers.
As the psychosocial workers have access to counselees’
medical files and also have their pedigree available they
are well informed; this avoids counselees having to discuss
their situation/issues again. Counselees are informed
about this procedure as part of the informed consent
procedure.
Details on the development of the actual intervention
will be published separately.
Quality of the intervention
All intervention sessions will be audio-recorded to: exam-
ine whether the psychosocial workers perform their task
according to the intervention protocol, trace differences
between the psychosocial workers, and monitor changes
in intervention delivery over time.
All recordings will be divided into four sets of 33 con-
secutive sessions. From each set 12 recordings will be
chosen, stratified by psychosocial worker, and analyzedto investigate whether psychosocial workers correctly
follow the steps of the intervention (Table 1). Scoring of
the 48 recordings will be based on an adapted version of
an instrument developed earlier [41].
Primary outcome measures
At T2 the primary outcomes will be assessed by question-
naire (and partly by telephone) using specific instruments
(Figure 1). Details on the development and psychometric
properties of the outcome measures will be published
separately.
Knowledge will comprise counselees’:
1. Insight into which relatives need to be informed,
as indicated by a percentage ‘correct knowledge’
specifying the relative number of family members
that need to be informed, correctly remembered by
the counselee (range 0 to 100).
2. Knowledge about surveillance measures for relatives,
as indicated by the percentage ‘correct knowledge
about surveillance options’ that indicates how many
screening options for relatives (1 to 6), are correctly
remembered by the counselee (range 0 to 100).
3. Risk perception, as measured with two items:
perceived lifetime breast and/or ovarian or colon
cancer risk in percentages, and perceived breast
and/or ovarian or colon cancer risk as compared
with the average Dutch woman or person
(5-point Likert scale: 1 = very strongly lowered,
5 = very strongly heightened).
4. General knowledge about hereditary breast or
colon cancer, which includes six items developed by
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[14]. All items are presented as statements with
three response categories (‘Correct’, ‘Incorrect’,
or ‘I do not know’). A higher score indicates
more knowledge about hereditary cancer.
Motivation
Counselees’ motivation to inform relatives will be
assessed using a 30-item instrument based on a 36-item
questionnaire developed by Finlay et al. [43]. All items are
potential determinants of disclosure of information to rela-
tives and are answered on a 5-point Likert scale (1 = plays
no role in disclosure, 5 = plays a large role in disclosure).
Items will be presented to participants as: ‘Reasons to in-
form relatives’ (positive motivation, 13 items) and ‘Reasons
for not informing relatives’ (negative motivation, 17 items).
For each scale a total score is created, with a higher score
indicating more positive or negative motivation to inform
relatives (range 13 to 65 and 17 to 85, respectively).
Self-efficacy
Self-efficacy is the measure of one’s own ability to com-
plete tasks and reach goals [44]. Index patients will be
asked to indicate how sure they are that they are able to
overcome seven obstacles in informing relatives, on a
4-point Likert scale (1 = not sure at all, 4 = very sure).
A total score is created, with a higher score indicating
more self-efficacy (range 7 to 28).
Secondary outcome measures
Secondary outcome measures include the following:
1. Relatives’ knowledge, which will be assessed using
the same instruments as used by counselees,
comprising knowledge about surveillance, risk
perception and general knowledge about hereditary
breast and/or ovarian cancer or colon cancer.
2. Relatives’ intention to engage in genetic counseling,
testing and/or preventive measures, measured with six
items using the following format ‘How likely is it that
you will have a colonoscopy in the coming year?’ Items
are scored as 1 = very unlikely, to 5 = very likely [45].
3. Relatives’ evaluation of the way they have been
informed, which includes seven items about the
way relatives are informed and their evaluation
of the communication process. Items were
developed for the purpose of this study and are
based on those developed by Vos et al. [46].
4. Counselees’ evaluation of the intervention, which
includes 18 questions about the intervention and
its content, psychosocial workers’ performance,
and practical issues related to the intervention
(for example, right moment in time, intervention
conducted by telephone).5. Psychosocial workers’ evaluation of the intervention,
in which psychosocial workers are asked to
complete ten items after each additional counseling
session to evaluate the intervention. The aim is to
gain insight into their experiences with the
intervention, to identify issues to improve the
intervention, and to track (in) congruence between
counselees’ and psychosocial workers’ experiences
with the intervention.
Counselees’ characteristics
Counselees’ characteristics include the following:
1. Demographic variables, which include age,
gender, educational level, age of their children,
and marital status.
2. Clinical characteristics, comprising genetic
test result, cancer diagnosis, number of relatives
to be informed, number of informed relatives
(as reported by the counselee), age at which
the counselee was first confronted with cancer in
the family, and types of cancer in the family.
Sample size
For the primary research question we aim for a medium
effect size. At baseline (T1), we assume no differences in
primary outcomes between the intervention and control
group. At T2 we expect to find a medium effect size.
We assume this to be 0.5 for the intervention group and
0.2 for the control group, taking into account that the
outcomes in the control group may be slightly affected
by that fact that they are aware that the study focuses on
informing their relatives; this effect is estimated to last
until follow-up (T3).
Based on these assumptions, we require 132 patients
in each group to have 80% power to detect an interven-
tion effect (group/time interaction) that is significant at
the 0.05 level (assuming a 0.7 correlation between mea-
surements). In addition, we have a 99% chance to detect
differences between measurement moments and a 46%
chance to detect group differences overall.
Assuming a response rate of 50% and a 20% dropout,
we need to approach 660 counselees. Preliminary work
has shown that counselees are advised to inform (on
average) 4.6 at-risk relatives. Assuming that counselees
provide contact information for (on average) two rela-
tives and that 50% of these relatives will complete the
questionnaire, it is estimated that we will have data on
264 relatives.
Randomization
ALEA (a software package to support online randomi-
zation in healthcare research) will be used to randomly
allocate the participant to either the intervention or
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system ensures allocation concealment. In order to create
equal comparison groups and prevent allocation bias,
randomization will be stratified for three different groups
(that is, conclusive versus inconclusive DNA test result)
and whether or not the counselee has been diagnosed with
cancer. To balance group sizes, random block rando-
mization will be used with a maximum block size of 8 and
block size factor 5.
Blinding
The informed consent procedure to postpone informa-
tion enables a blind design for participants in the control
group. Participants in the intervention group will be
masked for the exact study objective to avoid biased
outcome measures. Psychosocial workers and research
assistants who collect data cannot be blinded. At T2,
research assistants will obtain outcome measures by
telephone. To ensure that the outcomes are obtained as
objectively as possible, a telephone script has been devel-
oped to minimize individual differences between research
assistants. Also, to minimize additional bias, data entry is
performed by someone other than the person who per-
forms the analyses.
Data analysis
All analyses will be based on the intention-to-treat
principle. Assuming random dropout, incomplete data
will be imputed using data of the control group, that is,
standard care.
Hypothesis 1: Multilevel analysis will be used to inves-
tigate whether the intervention increases counselees’
knowledge, motivation and self-efficacy as compared
with the control group. Effects of the intervention will
be investigated on each of the seven outcome variables
separately. The three moments of measurement (T1, T2,
T3) will be treated as nested within counselees.
Hypothesis 2: Multilevel analysis will also be used to
investigate whether the intervention increases: the num-
ber of correctly informed relatives; relatives’ knowledge
about hereditary/familial cancer and preventive measures;
and relatives’ intention to engage in genetic counseling.
For this, the relatives will be treated as nested within
counselees and counselees will be treated as nested within
physicians.
Hypothesis 3: To investigate how counselees and psy-
chosocial workers evaluate the intervention, descriptives
and frequencies will be calculated to present counselees’
and psychosocial workers’ evaluation of the intervention.
Ethical and safety issues
The study has been approved by the Medical Ethics
Committee of AMC (MEC 2012-02) and recruitment of
the participants is in progress. The study is conductedaccording to the principles of the Declaration of Helsinki
and in accordance with the Medical Research Involving
Human Subjects Act. After participants have given in-
formed consent, each participant receives an individual
ID number to secure anonymity. The web-based ques-
tionnaires can only be completed by participants with
this unique number and data from these questionnaires
are collected on a secured server. In accordance with the
act, the investigator will inform the participants and the
accredited Medical Ethics Committee if anything occurs
from which it appears that the disadvantages of partici-
pation may be significantly greater than was foreseen in
the research proposal.Discussion
A multicenter RCT is proposed to support counselees in
disclosing hereditary or familial cancer risk information
to at-risk relatives. The aim of the intervention is to
evaluate the effectiveness of an additional telephonic
counseling session performed by psychosocial workers.
Genetic counselors rely on counselees to inform their
relatives about their hereditary or familial cancer risk
and the possibilities to reduce this risk. Therefore, it is
important to maximize their ability to be a competent,
motivated and confident informant while respecting their
wish not to inform (some) relatives. The proposed inter-
vention aims to support counselees in this difficult task
and hopefully allow more at-risk relatives to make a well-
informed decision. If effective, this intervention might lead
to more relatives taking up genetic services and preventive
screening and possibly reducing cancer morbidity and
mortality in these affected families.
This is not the first intervention to enhance family
communication about genetic testing and hereditary risk
information [28-30]. However, to our knowledge, this is
the first to 1) study the effectiveness of additional sup-
port using a randomized controlled design based on MI,
2) apply an intervention for mutation carriers and coun-
selees with relatives with an increased risk to develop
cancer, and 3) involve relatives in the study. Another
strength is that the psychosocial workers delivering the
intervention are specialized in genetics, are experts in
working with cancer counselees, have well-developed
communication skills, and are likely to have more time
to deliver the intervention than clinical geneticists and/
or genetic counselors.
Some limitations also need to be addressed. First, our
patient sample is not truly representative for cancer
counselees in general, since only index patients are invited
to participate; this may affect the external validity. We did
consider inviting all counselees who were advised to
inform at-risk relatives, but rejected this idea because of
the complexity of establishing which relatives have already
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med by other relatives about their risk to develop cancer.
Second, similarity of the two study arms is not guaran-
teed since participants in the intervention arm receive
more attention than the controls. Therefore, it is difficult to
precisely define the effective components of the interven-
tion. Also, a third study arm, comprising a condition with
only a telephone call was considered to be too ambitious
given the additional number participants required. How-
ever, to gain insight into the effective components of the
intervention, we aim to compare the group of counselees
who only needed the first phase of the intervention (that
is, systematically exploring disclosure of genetic cancer in-
formation to at-risk relatives) with those who also received
the second phase of the intervention (that is, building mo-
tivation, self-efficacy, brainstorming).
Moreover, pilot work revealed the complexity of gaining
reliable insight into the counselees’ knowledge regarding
which relatives to inform and what to tell relatives by
asking them to complete questionnaires. Therefore, com-
pletion of the questionnaire after the intervention (T2) is
done (in part) by telephone to ensure that the counselees
understand the items correctly. This telephone call, per-
formed by the researchers, might be seen as an inter-
vention on its own, since counselees are asked about
family communication in a systematic way. For that
reason, the telephone call is scripted and standardized
as far as possible.
Finally, studies in which relatives are invited to partici-
pate, including the present study, have some limitations.
Medical-ethical regulations preclude geneticist/researchers
from directly approaching the relatives of counselees.
Therefore, we ask the participating counselees to invite
their relatives to participate; this may cause some selection
bias since only those relatives can be invited who have
been correctly informed by the counselee. To prevent this
bias, we use the pedigree of the participant, and for each
individual relative, we systematically ask whether this rela-
tive may be invited or not.
This paper is the first of a series that will outline the
development and testing of an intervention to enhance
family communication about hereditary or familial can-
cer risks; here we describe the study protocol of the
RCT. Additional papers will describe the development
and psychometric properties of the outcome measures,
pilot testing, and the outcomes of the trial.
Trial status
A pilot study has been performed and recruitment for the
trial is in progress. Data collection will continue until
summer 2014.
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